← Scroll for more →
Financial Statements — LIPO
Balance Sheet
(in millions USD)| Metric | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 1.86 | 2.78 | 4.23 | 2.18 | 1.35 | 1.19 | 2.11 | 3.29 | 2.41 | 3.11 | 4.02 | 5.12 |
| Short-term Investments | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.30 |
| Accounts Receivable | -- | -- | -- | 0.08 | 0.03 | 0.04 | 0.07 | 0.03 | 0.05 | 0.03 | 0.08 | 0.11 |
| Total Current Assets | 2.08 | 3.44 | 4.82 | 2.62 | 2.08 | 2.08 | 3.01 | 3.43 | 2.67 | 3.37 | 4.48 | 5.80 |
| Property, Plant & Equipment | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | -- | -- | -- |
| Total Non-current Assets* | 0.27 | 0.28 | 0.03 | 0.06 | 0.08 | 0.10 | 0.13 | 0.15 | 0.17 | 0.13 | 0.13 | 0.13 |
| Total Assets | 2.35 | 3.72 | 4.86 | 2.67 | 2.16 | 2.18 | 3.14 | 3.58 | 2.84 | 3.49 | 4.61 | 5.95 |
| Accounts Payable | 0.46 | 0.61 | 0.39 | 0.39 | 0.46 | 0.18 | 0.29 | 0.14 | 0.30 | 0.02 | 0.15 | 0.38 |
| Total Current Liabilities | 0.64 | 0.75 | 0.78 | 0.75 | 0.70 | 0.48 | 0.55 | 0.39 | 0.55 | 0.30 | 0.72 | 1.18 |
| Total Non-current Liabilities* | 0.22 | 0.23 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.05 | 0.07 | 0.07 | 0.08 | 0.10 |
| Total Liabilities | 0.86 | 0.98 | 0.78 | 0.75 | 0.70 | 0.48 | 0.58 | 0.43 | 0.62 | 0.36 | 0.80 | 1.27 |
| Retained Earnings | (19.23) | (17.97) | (16.65) | (15.34) | (13.90) | (12.45) | (11.52) | (10.32) | (9.63) | (8.31) | (6.77) | (5.70) |
| Total Stockholder Equity | 1.49 | 2.74 | 4.08 | 1.92 | 1.46 | 1.70 | 2.56 | 3.14 | 2.22 | 3.13 | 3.82 | 4.68 |
← Scroll for more columns →
* Derived from reported values
Income Statement
(in millions USD) (except per-share rows)| Metric | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.09 | 0.13 | 0.17 | 0.08 | 0.14 | 0.15 | 0.12 | 0.10 | 0.11 | 0.12 |
| Research & Development | 0.72 | 0.79 | 0.99 | 1.06 | 1.05 | 0.66 | 0.84 | 0.45 | 0.83 | 1.06 | 0.69 |
| Selling, General & Admin | 0.55 | 0.65 | 0.46 | 0.56 | 0.49 | 0.43 | 0.52 | 0.40 | 0.63 | 0.62 | 0.51 |
| Operating Income | (1.27) | (1.36) | (1.33) | (1.45) | (1.46) | (0.95) | (1.22) | (0.73) | (1.36) | (1.58) | (1.08) |
| Interest Expense | -- | -- | -- | -- | -- | -- | -- | 0.00 | 0.00 | 0.01 | 0.01 |
| Pretax Income | (1.25) | (1.33) | (1.31) | (1.44) | (1.44) | (0.94) | (1.19) | (0.69) | (1.32) | (1.54) | (1.07) |
| Net Income | (1.25) | (1.33) | (1.31) | (1.44) | (1.44) | (0.94) | (1.19) | (0.69) | (1.32) | (1.54) | (1.07) |
| Basic EPS | (0.28) | (0.31) | (0.64) | (3.22) | (1.29) | (0.12) | (0.16) | (0.08) | (0.23) | (0.27) | (0.19) |
| Diluted EPS | (0.28) | (0.31) | (0.64) | (3.22) | (1.29) | (0.12) | (0.16) | (0.08) | (0.23) | (0.27) | (0.19) |
← Scroll for more columns →
Cash Flow Statement
(in millions USD)| Metric | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | (0.93) | (1.43) | (1.43) | (0.99) | (0.65) | (0.92) | (1.39) | (0.73) | (0.69) | (0.66) | (1.08) |
| Capital Expenditures | -- | -- | -- | -- | -- | -- | -- | -- | 0.01 | -- | -- |
| Free Cash Flow* | -- | -- | -- | -- | -- | -- | -- | -- | (0.70) | -- | -- |
| Investing Cash Flow | -- | -- | -- | -- | -- | -- | -- | 0.00 | 0.00 | 0.60 | (0.30) |
| Financing Cash Flow | 0.00 | (0.01) | 3.47 | 1.82 | 0.82 | 0.00 | 0.20 | 1.61 | 0.00 | (0.25) | (0.02) |
← Scroll for more columns →
* Derived from reported values